Studies involving circulating miRNAs in hematological diseases
| Disease . | Analyzed aspect . | Number of deregulated/analyzed miRNAs . | Most important candidate miRNAs . | Profiling method . | Reference . |
|---|---|---|---|---|---|
| Serum/plasma-based studies | |||||
| ATL | Identification of miRNA markers for the diagnosis and classification of acute and chronic ATL | 5/>200 | miR-155 ↑pp | Microarray; qRT-PCR | 63 |
| let-7g | |||||
| miR-126 ↓pp | |||||
| miR-130a | |||||
| let-7b | |||||
| CLL | Identification of clinically relevant plasma miRNAs in CLL | 27/333 | miR-150/150* | Multiplexing qRT-PCR (Applied Biosystems) | 65 |
| miR-20a | |||||
| miR-29a | |||||
| miR-135a* | |||||
| DLBCL | Utility of cancer-associated miRNAs for DLBCL diagnosis | 3/3 | miR-21 ↑gp | TaqMan qRT-PCR | 57 |
| Suitability of serum miRNAs for DLBCL detection | 5/7 (1↓, 4↑) | miR-15a, -16-1 ↑ | TaqMan qRT-PCR | 58 | |
| miR-29c, -155 ↑ | |||||
| miR-34a ↓ | |||||
| MDS | Suitability of 2 plasma miRNAs to predict survival in MDS patients | 2/2 | let-7a ↓gp | qRT-PCR (Applied Biosystems) | 59 |
| miR-16 ↓gp | |||||
| MM | Identification of diagnostic miRNA markers in MM | 3/9detected | miR-720† | Human miRNA microarray (Agilent), TaqMan qRT-PCR | 60 |
| miR-1308 | |||||
| miR-1246 | |||||
| Expression dynamics of miR-17-92a in MM | 25/381 | miR-17-92a ↓ | TaqMan Low Density Arrays, qRT-PCR | 53 | |
| (20↓, 5↑) | miR-223 ↓ | ||||
| Prognostic utility of plasma miRNAs | 5/667 | miR-20a ↑pp | TaqMan Low Density Arrays, qRT-PCR | 61 | |
| miR-148a ↑pp | |||||
| miR-99b ↑t(4;14) | |||||
| miR-221 ↑del(13q) | |||||
| NHL | Suitability of miR-92a for diagnosis and NHL treatment monitoring | 1/470 | miR-92a ↓ | Agilent miRNA Microarrays version 1.5, TaqMan qRT-PCR | 54 |
| NKTL | Diagnostic and prognostic value of circulating miR-221 | NA | miR-221 | Direct qPCR without RNA extraction | 55 |
| CSF-based studies | |||||
| DLBCL | Identification of diagnostic miRNAs in CSF of DLBCL patients | 3/6 | miR-21 ↑ | TaqMan qRT-PCR | 56 |
| miR-19 ↑ | |||||
| miR-92a ↑ | |||||
| Disease . | Analyzed aspect . | Number of deregulated/analyzed miRNAs . | Most important candidate miRNAs . | Profiling method . | Reference . |
|---|---|---|---|---|---|
| Serum/plasma-based studies | |||||
| ATL | Identification of miRNA markers for the diagnosis and classification of acute and chronic ATL | 5/>200 | miR-155 ↑pp | Microarray; qRT-PCR | 63 |
| let-7g | |||||
| miR-126 ↓pp | |||||
| miR-130a | |||||
| let-7b | |||||
| CLL | Identification of clinically relevant plasma miRNAs in CLL | 27/333 | miR-150/150* | Multiplexing qRT-PCR (Applied Biosystems) | 65 |
| miR-20a | |||||
| miR-29a | |||||
| miR-135a* | |||||
| DLBCL | Utility of cancer-associated miRNAs for DLBCL diagnosis | 3/3 | miR-21 ↑gp | TaqMan qRT-PCR | 57 |
| Suitability of serum miRNAs for DLBCL detection | 5/7 (1↓, 4↑) | miR-15a, -16-1 ↑ | TaqMan qRT-PCR | 58 | |
| miR-29c, -155 ↑ | |||||
| miR-34a ↓ | |||||
| MDS | Suitability of 2 plasma miRNAs to predict survival in MDS patients | 2/2 | let-7a ↓gp | qRT-PCR (Applied Biosystems) | 59 |
| miR-16 ↓gp | |||||
| MM | Identification of diagnostic miRNA markers in MM | 3/9detected | miR-720† | Human miRNA microarray (Agilent), TaqMan qRT-PCR | 60 |
| miR-1308 | |||||
| miR-1246 | |||||
| Expression dynamics of miR-17-92a in MM | 25/381 | miR-17-92a ↓ | TaqMan Low Density Arrays, qRT-PCR | 53 | |
| (20↓, 5↑) | miR-223 ↓ | ||||
| Prognostic utility of plasma miRNAs | 5/667 | miR-20a ↑pp | TaqMan Low Density Arrays, qRT-PCR | 61 | |
| miR-148a ↑pp | |||||
| miR-99b ↑t(4;14) | |||||
| miR-221 ↑del(13q) | |||||
| NHL | Suitability of miR-92a for diagnosis and NHL treatment monitoring | 1/470 | miR-92a ↓ | Agilent miRNA Microarrays version 1.5, TaqMan qRT-PCR | 54 |
| NKTL | Diagnostic and prognostic value of circulating miR-221 | NA | miR-221 | Direct qPCR without RNA extraction | 55 |
| CSF-based studies | |||||
| DLBCL | Identification of diagnostic miRNAs in CSF of DLBCL patients | 3/6 | miR-21 ↑ | TaqMan qRT-PCR | 56 |
| miR-19 ↑ | |||||
| miR-92a ↑ | |||||
ATL, adult T-cell leukemia; BL, Burkitt lymphoma; gp, associated with good prognosis; NHL, non-Hodgkin lymphoma; NKTL, extranodal natural killer/T-cell lymphoma; pp, associated with poor prognosis; NA, lacked access to the paper; CLL, chronic lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma; CSF, cerebrospinal fluid; Arrows, up or down regulation.
This has been identified as not a true miRNA (dead miRBase entry).